Palvella Therapeutics (PVLA) Income towards Parent Company (2016 - 2024)
Historic Income towards Parent Company for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' Income towards Parent Company fell 12854.56% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 7402.68%. This contributed to the annual value of -$17.4 million for FY2024, which is 19327.48% down from last year.
- Per Palvella Therapeutics' latest filing, its Income towards Parent Company stood at -$4.0 million for Q4 2024, which was down 12854.56% from -$6.8 million recorded in Q3 2024.
- Over the past 5 years, Palvella Therapeutics' Income towards Parent Company peaked at $13.8 million during Q4 2023, and registered a low of -$19.0 million during Q3 2021.
- In the last 5 years, Palvella Therapeutics' Income towards Parent Company had a median value of -$9.2 million in 2021 and averaged -$7.8 million.
- As far as peak fluctuations go, Palvella Therapeutics' Income towards Parent Company plummeted by 150869.0% in 2020, and later skyrocketed by 22393.45% in 2023.
- Quarter analysis of 5 years shows Palvella Therapeutics' Income towards Parent Company stood at -$12.4 million in 2020, then rose by 11.27% to -$11.0 million in 2021, then decreased by 1.48% to -$11.2 million in 2022, then surged by 223.93% to $13.8 million in 2023, then crashed by 128.55% to -$4.0 million in 2024.
- Its Income towards Parent Company stands at -$4.0 million for Q4 2024, versus -$6.8 million for Q3 2024 and -$4.2 million for Q2 2024.